Recommendations present the current management, that may be modified and changed in certain cases, after a thorough analysis of a given clinical situation, which in the future may be the basis for their modification and actualization.

SUMMARY OF THE RECOMMENDATIONS

Definitions

Fetal Growth Restriction (FGR) — a synonym for intrauterine growth restriction (IUGR)

< 32 weeks — early-onset FGR; > 32 — late onset FGR

Hypotrophy — a term related to a newborn with growth restriction

Risk factors

Risk factors of growth restriction should be assessed in every woman at the beginning of pregnancy and at each following visit (Tab. 1A and 1B). Increased risk of FGR is diagnosed if, at least one major or three minor risk factors are present. Risk may also be determined using an algorithm combining ultrasound, medical history, and serum markers.

Confirming the gestational age

Each pregnant woman should undergo an ultrasound examination between 11–13 + 6 weeks of gestation, during which the crown-rump length is measured, and the date of delivery is determined. If there is no ultrasound examination at this time, the delivery date should be determined on the basis of HC and FL measurements in the second trimester of pregnancy.

Differential diagnosis

Suspicion of abnormal growth should be followed by a detailed work up to determine the potential cause (chromosomal abnormalities, infections, congenital anomalies, impaired blood flow in the uterine arteries, changes in the placenta).

Growth assessment

The recommended method of calculating the estimated fetal weight is the Hadlock equation. AC and HC measurements should be made using an ellipse to cover the outer contours of the abdomen and fetal head. Based on availability and accessibility, PSOGO recommends the use of
the Hadlock growth charts until the development and dissemination of growth standards for the Polish population.

Fundal height assessment should be performed in low-risk pregnancies starting from the 24th week of gestation.

**Diagnosis and management**

We recommend FGR diagnosis based on ultrasound criteria reported in the Delphi consensus. After the diagnosis, management is always individualized, and surveillance should incorporate all the available tools. Management is feasible in an outpatient setting. Hospitalization is indicated if FGR is accompanied by:

- oligohydramnios
- abnormal CTG tracings
- abnormal biophysical profile
- vaginal bleeding
- reduced or rapid fetal movements
- absent or reversed end diastolic flow in the umbilical artery
- CPR < 5 percentile
- absent or reversed end diastolic flow in the ductus venous
- other symptoms of fetal distress

**Delivery**

Choice of timing and mode of delivery depends on the severity of FGR, accompanying abnormalities in CTG trac-
ings and ultrasound assessment. In the absence of previous indications, delivery is recommended not later than week 37.

**ABBREVIATIONS AND DEFINITIONS**

AC — abdominal circumference  
AEDV — absent end diastolic velocity  
AGA — appropriate for gestational age — fetuses and neonates with estimated fetal weight and neonatal weight between the 10–90 percentile  
AOR — adjusted odds ratio  
APLS — antiphospholipid syndrome  
ARR — adjusted relative risk  
BMI — body mass index  
BPD — biparietal diameter  
CPR — cerebro-placental ratio  
CRL — crown-rump-length  
DV — Ductus Venous  
Early-onset FGR — early onset growth restriction, onset before 32 weeks of gestation  
FGR — fetal growth restriction — is the failure of the fetus to achieve the programmed birth weight after excluding internal factors (chromosomal aberrations, infections, birth defects)  
FL — femur length  
HC — head circumference  
Hypotrophy - a term related to a newborn born with growth restriction  
IUGR — intrauterine growth restriction — synonym of FGR  
Late-onset FGR — late onset fetal growth restriction, onset after 32 weeks of gestation  
LGA — large for gestational age — fetuses and neonates with estimated fetal weight and neonatal weight above the 90 centile  
MCA — middle cerebral artery  
OR — odds ratio  
PIGF — placental growth factor  
REDV — reverse end diastolic velocity  
RR — relative risk  
SGA — small-for-gestational-age — fetuses with estimated weight (EFW) on ultrasound between the 3rd and 10th percentile for gestational age without signs of growth failure or newborns with birth weight below the 10th percentile  
TORCH — Toxoplasmosis, Rubella, Cytomegalovirus, Herpes simplex  
UA — umbilical artery  
UtA — uterine artery  
ARSA — aberrant right subclavian artery

**AIM**

The aim of these recommendations is to present FGR management principles based on currently available scientific evidence and clinical experience.

**INTRODUCTION**

Fetal Growth Restriction (FGR) is a clinical situation in which the fetus does not reach its programmed birth weight [1]. Currently, there are two types of fetal growth restriction. Early-onset FGR before 32 weeks of gestation. Early FGR often coexists with maternal hypertension or connective tissue disease [2]. In the TRUFFLE study, pre-eclampsia was found in 75% of pregnancies included in the study [3]. Early FGR is an indication to refer the patient to a higher reference level and is primarily a challenge in terms of planning appropriate management. The natural course of the disease is relatively well understood. The GRIT and TRUFFLE studies analyzed the effectiveness of various diagnostic and therapeutic regimens and their impact on the outcomes of perinatal care (both early and late) [3–5]. According to experts, much more controversy exists around late FGR, which is defined as growth restriction that occurs after 32 weeks of gestation. In these cases, the primary problem is diagnosis in low-risk pregnancies, as in many countries, third trimester ultrasound examination in this group of women is not recommended (Tab. 2). FGR detection in low-risk pregnancies in many countries does not exceed 15% [2, 6, 7]. In Poland, it is currently recommended to perform an ultrasound scan in the third trimester.
between 28–32 weeks of pregnancy and at term [8, 9]. In Poland, despite routine performance of the third trimester ultrasound, this detection rate is not much higher [10]. One of the greatest challenges of modern perinatology is the prevention of intrauterine deaths [11]. The experience from Great Britain shows that the identification of women with an increased risk of growth failure, staff training, the introduction of diagnostic and therapeutic recommendations and guidelines gives a chance to reduce perinatal mortality [12].

Risk factors
Risk factors for growth restriction should be assessed in every woman at the beginning of pregnancy and at each following visit. FGR risk factors can be classified as major or minor depending on the OR, AOR or RR (Tab. 1A and 1B). These are risk factors identified on the basis of maternal history and the course of current pregnancy. The diagnosis of an increased risk of FGR is based on the presence of at least one major risk factor or three minor risk factors [13]. The screening tests and preventive measures are described in detail later in the recommendations. A high risk of FGR in the first trimester of pregnancy is an indication to consider prophylactic administration of acetylsalicylic acid [14].

Pregnant women in Poland rarely admit to smoking. It is also difficult to obtain reliable information regarding their home exposure to cigarette smoke. According to data published for the Polish population, 12% of women continue to smoke during pregnancy [15]. Therefore, the risk should not be differentiated depending on the number of cigarettes smoked or the environmental exposure. If the patient reports that she had stopped smoking in the first trimester, we classify it as a major risk factor of FGR.

**DIAGNOSIS AND MANAGEMENT**

**Differential diagnosis**

**Confirmation of gestational age**

The basic criterion for the assessment and diagnosis of growth abnormalities is the correct determination of the duration of pregnancy. Measuring the CRL between 8 and 14 weeks of gestation is considered the most accurate method of assessing the duration of pregnancy [16]. Currently, according to the PSOGO recommendations, every pregnant woman should undergo an ultrasound examination between 11–13 + 6 weeks of gestation. In such a case, the measurement of the crown-rump length should be performed, and the date of delivery be determined on its basis. If the duration of pregnancy has been determined at that time, it should not be recalculated on the basis of subsequent ultrasound examinations [8]. If data on CRL is unavailable, then the HC and FL measurements can be used to determine the duration of pregnancy in the second trimester [16].

**Risk assessment of chromosomal abnormalities**

One third of early-onset FGR may coexist with chromosomal abnormalities or genetic syndromes [17]. Therefore, if FGR is diagnosed before 24 weeks of gestation, the risk of chromosome aberrations should be verified. A detailed interview regarding what genetic and screening tests have been performed so far by the patient is helpful. The medical documentation should include an annotation whether the first trimester screening was performed in accordance with the recommendations of PSOGO. If not — it should be noted in the documentation whether this was discussed and offered to the patient.

The indications for invasive genetic testing in the case of FGR are as follows:
- Early FGR < 24 weeks
- Major structural defects accompanying FGR
- Presence of benign ultrasound markers indicating an increased risk of aneuploidy (nuchal fold thickening, ventriculomegaly, ARSA, choroid plexus cysts, incorrect hand position, septal defects, hypertrophic bowel, shortened humerus, hypoplastic nasal bone < 10 percentile).

If the ultrasound examination does not show signs of placental insufficiency, and the patient has not had the first trimester screening in accordance with the FMF and PSOGO standards, or if, despite being at high risk, further screening was not performed (free fetal DNA testing), then amniocentesis or cordocentesis should be offered.

**Diagnosis of TORCH infections**

FGR suspicion should prompt diagnosis of cytomegaly, toxoplasmosis, rubella and herpes simplex. In Poland, routine malaria diagnosis is not recommended, although in selected cases, justified by medical history, it may be suggested.

Invasive diagnosis to confirm fetal infection should be considered individually. Amniocentesis should not be performed before 18 weeks of gestation and not earlier than 4 weeks after the onset of maternal symptoms. The indications for amniocentesis can be both the results of serological tests (the presence of specific IgM and IgG antibodies with low avidity of IgG antibodies) [18], as well as ultrasound assessment performed by an experienced professional or in a dedicated prenatal diagnosis center (cerebral, liver microcalcifications, ventriculomegaly, microcephaly, hepatomegaly, effusion in body cavities, fetal edema and placentomegaly) [19].

**Anatomy assessment**

FGR is an indication for a detailed assessment of fetal anatomy. The scope of ultrasound workup depends on the gestational age. Estimated fetal weight below the 3rd per-
Growth assessment

In a low-risk pregnancy, fetal growth should be assessed at week 20–22; 28–32 weeks and after 40 weeks, in accordance with the current standard of perinatal care and the PSOGO recommendations [8, 9] (Fig. 1). In a high-risk pregnancy, fetal growth should be assessed: at week 20–22; at week 26–28; at week 34–38 and week 40 [8] (Fig. 2). In the case of FGR diagnosis, the frequency of ultrasound examinations depends on the severity of growth restriction. Fetal weight assessment should be made in accordance with the Hadlock II methodology, considering the BPD, HC, AC and FL measurements. The AC and HC measurements should be made using an ellipse and cover the external outline of the fetal soft tissues [16].

When assessing the fetal growth, the use of population growth charts is recommended [20]. The Z-score can also be used, but the percentile method is more readable for the recipients [21].

An alternative are customized growth charts, which allow calculation of the optimal birth weight for a given pregnancy, accounting for the mother’s ethnic origin, her height and weight before pregnancy and parity [22]. However, in the light of previous reports, they do not demonstrate a predictive advantage. At the time of delivery, nearly 70% of fetuses with weight estimated between the 3rd and 10th centile is healthy, and their weight is exclusively constitutive (maternal constitutional conditions, race, fertility, BMI) [23]. When assessing the weight of the fetus and its centile, it is always worth paying attention to which specific measured parameter is responsible for the diagnosis of FGR. A low fetal weight percentile can sometimes be due to, for example, a relatively “shorter” FL measurement and may result in an unnecessary implementation of intensive care and invasive measures. At present, there are no recommendations to use customized growth charts for a given population, although it may be a more appropriate diagnostic method in the future [16]. Due to availability, PSOGO recommends using the Hadlock II algorithm until the Polish population standard is developed and disseminated.

Fundal height measurement

The fundal height measurement is an approximate method of assessing the stage of pregnancy and the size of the fetus. The result is influenced by maternal obesity, parity and the obstetrician’s experience. The assessment of fundal height can only be used as an indication for ultrasound assessment. It can be performed in low-risk pregnancies starting from the 24th week of gestation. It involves measuring the distance between the upper edge of the pubic symphysis and the floor of the uterus (SF, symphysis-fundal). The values and standard deviations of fundal height for a given gestational age according to Intergrowth are presented in Table 3. FGR is suspected when the SF measurement value is lower by 3 or more than 3 centimeters for a given gestational age [24]. This is an indication for an ultrasound
examination. Fundal height assessment is not indicated in patients with pre-pregnancy BMI > 35 and in women with large uterine fibroids.

Delphi Criteria for FGR

In 2016, in order to standardize the diverse nomenclature, a definition of FGR was developed through an international consensus. This definition applies to fetuses with placental growth failure, after excluding congenital abnormalities, TORCH infections and chromosomal abnormalities. Fetal growth restriction has been classified into early and late onset FGR. The diagnostic criteria are presented in Table 4 [25].

As a rough measure, early-onset fetal growth restriction begins before 32 weeks of gestation. For diagnosis, one of the following parameters must be identified:

- abdominal circumference (AC) measured by ultrasound < 3 percentile at a given gestational age,
- estimated fetal weight (EFW) measured by ultrasound < 3 percentile at a given gestational age,
- absent umbilical artery end-diastolic flow (UA AEDF) regardless of the estimated fetal weight.

The last of the above-mentioned parameters indicates impaired placental flow, which allows to distinguish a group of children with potentially impaired growth in the following weeks of gestation. Early-onset FGR may also be suspected when AC or EFW are lower than the 10th centile at a given gestational age, and the umbilical artery (UA) and/or uterine artery (UtA) pulsation index (PI) is greater than the 95th centile at a given gestational age.

Late-onset fetal growth restriction begins after 32 weeks of gestation. The diagnosis is made by the occurrence of a single parameter:

- abdominal circumference (AC) as measured by ultrasound < 3 centile for a given gestational age
- estimated fetal weight (EFW) < 3 centile for a given gestational age.

The diagnosis of late FGR can also be made when the estimated fetal weight or abdominal circumference is below the 10th percentile and at least one of the following criteria is met:

- growth inhibition above 2 quartiles (more than 50 centiles)
- CPR value (quotient of PI in MCA and UA) < 5 percentile
- UA PI > 95 percentile

As in the case of early FGR, the last two of the above-mentioned parameters indicate impaired placental flow, brain-sparing and impaired placental flow, i.e. they allow for identification of the group of children with potentially impaired growth in the following weeks of pregnancy.

Early fetal growth restriction

The management of early FGR, the frequency of fetal monitoring and the route of delivery depends on severity of the disease. In the TRUFFLE study, which compared computer CTG analysis and the assessment of Doppler blood flow values in DV in monitoring the well-being of the fetus, 85% of children in the second year of life had no neurological complications, and only 1% had cerebral palsy [4]. The most important risk factor for neonatal complications, including
Stage I
Stage I is diagnosed when the estimated fetal weight or abdominal circumference are below the 3rd percentile or when the fetal weight is between the 3–10th centile, with an increased uterine artery pulsatility index (mean PI > 95th centile or CPR < 5th centile or MCA < 5th centile). In this case, the blood flow should be assessed once a week together with an assessment of the amniotic fluid volume, and from 34 weeks of gestation, a CTG should be performed once a week. Abnormal values of ultrasound indicators, CTG parameters and/or progressing symptoms of pre-eclampsia.

Stage II
Stage II is diagnosed in the absence of end-diastolic flow in the umbilical cord. It is estimated that the risk of intrauterine death in the absence of end-diastolic flow in the umbilical cord is more than three times increased — OR = 3.59, with a 95% CI 2.29–5.62 [28]. This is an indication for urgent hospitalization of the patient. It is optimal to implement intensive cardiotocographic monitoring. Ultrasound examination should be performed 2–3 times a week. Blood flow in UtA, UA, MCA and DV is evaluated. CPR < 5th percentile and MCA < 5th percentile, therefore symptoms of circulatory centralization, which are only adaptive symptoms of the fetus, are not an indication for termination of pregnancy.

Stage III
Stage III is diagnosed when a retrograde wave in the umbilical cord or PI in DV > 95 centile are found. In this case, the risk of intrauterine death is also high — OR = 7.15, with a 95% CI of 5.22–9.81. It is optimal to introduce increased cardiotocographic monitoring. Ultrasound examination should be performed in a hospital setting every 12–24 hours. Pregnancy should be ended after 34 weeks of gestation, after a previous steroid therapy.

Stage IV
Stage IV is diagnosed when an absence of A wave, reverse A wave in DV or incorrect values of the CTG records are found. The patient must be hospitalized immediately, be under constant cardiotocographic supervision and should be given steroids. This is an indication for urgent termination of pregnancy by cesarean section.

Regardless of the abnormal values of vascular flow measurements assessed in Doppler examination, an indication for termination of pregnancy is reduced to < 3.5 short-term variability for > 40 minutes or repeated decelerations in cardiotocographic tracings [29–31]. The optimal place of hospitalization is a tertiary perinatal care center. Hospitalization is indicated pending results of cardiotocographic tracings, ultrasound assessment, the patient's condition and the coexistence of hypertension and pre-eclampsia indicators. The diagnosis of pre-eclampsia increases the severity of FGR by one level. In case of diagnostic doubts, lack of experience in ultrasound examination, or lack of appropriate equipment, it is recommended to refer the patient at any stage of gestation to a reference center or to a perinatal medicine specialist to determine further management.

Hospitalization is indicated in each case of FGR complicated by oligohydramnios (MVP < 2 or AFI < 5), abnormal biophysical profile, suspicious CTG recording, vaginal bleeding, reduced fetal movements or lack of end-diastolic flow in the umbilical artery.

The assessment of fetal movements after 30 weeks of gestation, according to the PSOGO recommendations, should take place during the periods of fetus' highest activity.
Supervision of fetal well-being during hospitalization in a reference center should be based on recommendations to ensure appropriate supervision, consistent with current medical knowledge.

The route of delivery should always be chosen individually, considering obstetric conditions, risk factors and experience of medical personnel, but also an increased risk of chronic fetal hypoxia in the event of impaired fetal well-being with an indication for caesarean section. After the completion of 37 weeks of gestation, in the presence of indications for its termination and no contraindications to vaginal delivery, it is recommended to induce labor with continuous cardiotocographic monitoring. FGR is a contraindication to vaginal delivery in case of breech position of the fetus. In case of pregnancy with FGR and the need to deliver < 32 weeks, it is recommended to administer magnesium sulphate (MgSO4) for neuroprotection of the fetus.

**Late fetal growth restriction**

In the case of late-onset FGR, the biggest problem is its diagnosis and differentiation between the growth-restricted fetus and a constitutionally small fetus (SGA). The SGA fetus’ growth potential is most likely inherited from its parents. Its growth parameters are within 3–10 percentile, but the blood flow in the uterine arteries, the umbilical cord, and the middle cerebral artery is normal. Such fetuses are, in most cases, healthy. Termination of pregnancy should occur at the time of delivery at the latest, in accordance with the PSOGO recommendations on labor induction [33].

Supervision of such fetuses requires an evaluation of growth dynamics and the blood flow in the vessels every 2 weeks. In low-risk populations, the number of SGA diagnosed at term does not exceed 15%. In studies involving populations similar to the Polish one, despite of performing the commonly recommended examination between 28 and 32 weeks of gestation, the rate of such fetuses in low-risk pregnancies was 19%, and in high-risk pregnancies 47% [10]. Therefore, it is extremely important to select patients who require additional ultrasound examination between 32–40 weeks of gestation.

In late FGR, we rarely observe an abnormal blood flow spectrum in the uterine arteries, but Figueras et al. [27] showed that the evaluation of blood flow in these vessels, also in pregnancies over 32 weeks, allows for identification of fetuses with an increased risk of perinatal complications. In the DIGITAT study, AEDV was found in only 10% of patients, and the mean PI values in the umbilical cord ranged from 0.93–0.98 [34]. In late FGR, the most useful is the evaluation of CPR or MCA flow, and the values of these parameters < 5 percentile allow for identification of fetuses in which pregnancy should be terminated earlier [27]. Induction of labor at 37 weeks of gestation is indicated for fetuses with an estimated weight below the 3rd percentile or with an abdominal circumference below the 3rd percentile. Early termination of pregnancy should be considered in the presence of symptoms of pre-eclampsia, depending on the results of cardiotocography and ultrasound examinations. If CPR is < 5th percentile or MCA flow is < 5th percentile, the ductus venous blood flow should be assessed and the management like for early FGR should be introduced. The other indications for hospitalization, CTG surveillance, delivery route, counting fetal movements and assessment of the biophysical profile are the same as in early FGR. Regardless of whether we are dealing with late FGR or SGA, CTG and USG control should be implemented in the event of increased blood pressure, vaginal bleeding, uterine contractions and reduced fetal movements.

**Screening tests and and general prevention**

When compiling the management protocols, the authors considered different scenarios depending on whether the patient was screened and/or assessed for FGR risk in the first trimester of pregnancy. The scheme also assumes a situation when, despite the existing indications, the pregnant woman did not receive or did not start taking acetylsalicylic acid. The risk of FGR should be assessed at each stage of pregnancy. Scheme I presents the method of risk evaluation in the first and second trimesters of pregnancy, taking into account the lack of risk assessment based on ultrasound and biochemical parameters in the first trimester. In such case, it should be done based on the previously described risk factors (1A and 1B).

In a single pregnancy, the Polish Society of Gynecologists and Obstetricians recommends the use of prenatal screening between 11 and 13 + 6 weeks of pregnancy to evaluate the risk of early-onset FGR with Doppler evaluation of uterine blood flow (UtA), mean arterial pressure (MAP) and determine the value of placental growth factor (PIGF) in blood. In high-risk situations (> 1: 100), it is justified to start the administration of 150 mg of acetylsalicylic acid before 16 weeks of gestation and continue it until the 36th week [14] (Fig. 3).

According to the PSOGO standards, ultrasound examination should be performed at 11–14, 20 and 28–32 weeks of gestation. In a group at high risk of FGR and/or pre-eclampsia identified on the basis of the first trimester screening, a screening between 19–24 weeks of gestation should be considered using the patient’s history and UtA PI, MAP, PIGF and sFlt-1 evaluation. Ultrasound assessment of growth should be performed according to the scheme outlined for high-risk pregnancies (High-risk pregnancy management scheme).
However, in low-risk pregnancies, it may be considered to evaluate the uterine blood flow in the second and third trimesters. In the case of correct biometry and PI UT A > 95th percentile, we recommend an additional control of growth dynamics between 34-38.

Confirming the high risk of early-onset FGR/pre-eclampsia occurrence (> 1:100) entails an individualized approach in the form of every-day blood pressure measurements, weekly assessment of proteinuria and periodic evaluation of fetal biometry.

Placenta

Examination of the placenta: description of macroscopic changes in medical record documentation and possibly a histopathological examination.

REFERENCES


